Abemaciclib + Anastrozole + Letrozole
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Endometrial Carcinoma
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Trial Timeline
Oct 16, 2020 → Jul 1, 2027
NCT ID
NCT04469764About Abemaciclib + Anastrozole + Letrozole
Abemaciclib + Anastrozole + Letrozole is a phase 2 stage product being developed by Eli Lilly for Recurrent Endometrial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04469764. Target conditions include Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Endometrial Carcinoma were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04469764 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent Endometrial Carcinoma